A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Evolution of the anti-interferon beta (IFNβ) antibody response in multiple sclerosis patients : IgG subclass distribution, affinity maturation and clinical correlates
Multiple Sclerosis (MS), a chronic degenerative disease of the central nervous system, is characterized by demyelination, axonal damage, and inflammatory lesions in the white matter. Symptoms include neurological deficits, relapses and progressive disability. Three recombinant interferon beta (IFNβ) products and glatiramer acetate are licensed for treatment. They have been shown to reduce the frequency and severity of relapses and slow disease progression in about 30% of treated patients.doi:10.14288/1.0066981 fatcat:gwlag6fnybc3tp5fuokjyo5jla